Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.VTL · Entity 6306 | Director | May 23, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.10 · Expires 2028-05-22 | Direct | 29,538 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 29,538 · Balance 29,538 F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2018 Filed May 25, 2018 20:07 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 29,538 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001280776-18-000039 · wf-form4_152727882222142.xml · derivative · entry 1 SEARS LOWELL · CIK 0001189160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,538 Underlying: Common Stock · 29,538 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:37 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 45,022 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000051 · wf-form4_149574821641447.xml · derivative · entry 1 SEARS LOWELL · CIK 0001189160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 Underlying: Common Stock · 45,022 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.